ArticlePLoS medicine2020
Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts.
Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03814915 (DIabetes REsearCh on Patient straTification), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DIabetes REsearCh on Patient straTification
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Diagnostic accuracy of artificial intelligence models for imaging detection of hepatic steatosis through systematic review and meta analysis.Scientific reports · 2025Pooled it
- Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals.Nature medicine · 2021Trial
- Construction of a prognostic model for colorectal cancer based on clinical parameters and quantitative body composition using CT imaging.BMC medical imaging · 2026Article
- Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review.EClinicalMedicine · 2026Review
- Risk Assessment and Prediction of Hepatocellular Carcinoma in Noncirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2026Review
- Targeting the Gut-Liver Mitochondria Axis in MASLD: Mechanisms and Therapeutic Perspectives.Current medical science · 2026Review
- Associations of continuous glucose monitor derived time in range and glycaemic variability with diet lifestyle and demographics.Nature communications · 2026Article
- Diagnosis and grading of steatotic liver disease via clinical and laboratory data using machine learning.Scientific reports · 2026Article
- Predicting metabolic dysfunction-associated steatotic liver disease risk using patient-derived induced pluripotent stem cells.Stem cells translational medicine · 2026Article
- Artificial intelligence-based multiclass classification of etiologies in patients with elevated liver enzymes: A prospective cohort study.Hepatology forum · 2026Article
- Interpretable Machine Learning Models for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Non-Invasive Routine Clinical and Laboratory Data.International journal of general medicine · 2026Article
- Harnessing AI-driven approaches for detecting metabolic dysfunction-associated steatotic liver disease, assessing fibrosis, and stratifying hepatocellular carcinoma risk: a scoping review.Frontiers in oncology · 2026Review
- Integrated analysis of RNA-binding proteins in MAFLD: mechanistic insights and diagnostic biomarker potential via alternative splicing.Journal of bioenergetics and biomembranes · 2025Article
- Advances in artificial intelligence and precision nutrition approaches to improve maternal and child health in low resource settings.Nature communications · 2025Review
- Disease classification, diagnostic challenges, and evolving clinical trial design in MASLD.The Journal of clinical investigation · 2025Review
- Identification of tryptophan metabolism-related biomarkers for nonalcoholic fatty liver disease through network analysis.Endocrine connections · 2025Article
- Predicting metabolic dysfunction associated steatotic liver disease using explainable machine learning methods.Scientific reports · 2025Article
- Global trends in artificial intelligence applications in liver disease over seventeen years.World journal of hepatology · 2025Article
- Gut microbiota metabolites impact immunologic responses to antiretroviral therapy in HIV-infected men who have sex with men.Infectious diseases of poverty · 2025Article
- Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification.Non-coding RNA research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors at 20 institutions in 11 countries.
Funding
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is highly prevalent and causes serious health complications in individuals with and without type 2 diabetes (T2D). Early diagnosis of NAFLD is important, as this can help prevent irreversible damage to the liver and, ultimately, hepatocellular carcinomas. We sought to expand etiological understanding and develop a diagnostic tool for NAFLD using machine learning. METHODS AND
findingsWe utilized the baseline data from IMI DIRECT, a multicenter prospective cohort study of 3,029 European-ancestry adults recently diagnosed with T2D (n = 795) or at high risk of developing the disease (n = 2,234). Multi-omics (genetic, transcriptomic, proteomic, and metabolomic) and clinical (liver enzymes and other serological biomarkers, anthropometry, measures of beta-cell function, insulin sensitivity, and lifestyle) data comprised the key input variables. The models were trained on MRI-image-derived liver fat content (<5% or ≥5%) available for 1,514 participants. We applied LASSO (least absolute shrinkage and selection operator) to select features from the different layers of omics data and random forest analysis to develop the models. The prediction models included clinical and omics variables separately or in combination. A model including all omics and clinical variables yielded a cross-validated receiver operating characteristic area under the curve (ROCAUC) of 0.84 (95% CI 0.82, 0.86; p < 0.001), which compared with a ROCAUC of 0.82 (95% CI 0.81, 0.83; p < 0.001) for a model including 9 clinically accessible variables. The IMI DIRECT prediction models outperformed existing noninvasive NAFLD prediction tools. One limitation is that these analyses were performed in adults of European ancestry residing in northern Europe, and it is unknown how well these findings will translate to people of other ancestries and exposed to environmental risk factors that differ from those of the present cohort. Another key limitation of this study is that the prediction was done on a binary outcome of liver fat quantity (<5% or ≥5%) rather than a continuous one.
conclusionsIn this study, we developed several models with different combinations of clinical and omics data and identified biological features that appear to be associated with liver fat accumulation. In general, the clinical variables showed better prediction ability than the complex omics variables. However, the combination of omics and clinical variables yielded the highest accuracy. We have incorporated the developed clinical models into a web interface (see: https://www.predictliverfat.org/) and made it available to the community.
trial registrationClinicalTrials.gov NCT03814915.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.